{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:44:46Z","timestamp":1791945886576,"version":"4.3.4"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Cerliponase alfa is recombinant human tripeptidyl peptidase 1 (TPP1) delivered by i.c.v. infusion for CLN2, a pediatric neurodegenerative disease caused by deficiency in lysosomal enzyme TPP1. We report the pharmacokinetics (PK) and pharmacodynamics of cerliponase alfa, the first i.c.v. enzyme replacement therapy, characterized in a phase I\/II study. Escalating doses (30\u2013300\u00a0mg Q2W) followed by 300\u00a0mg Q2W for \u2265\u00a048\u00a0weeks were administered in 24 patients aged \u2265\u00a03\u00a0years. Concentrations peaked in cerebrospinal fluid (CSF) at the end of ~\u00a04\u2010hour i.c.v. infusion and 8\u00a0hours thereafter in plasma. Plasma exposure was 300\u20131,000\u2010fold lower than in CSF, with no correlation in the magnitude of peak concentration (C<jats:sub>max<\/jats:sub>) or area under the concentration\u2010time curve (AUC) among body sites. There was no apparent accumulation in CSF or plasma exposure with Q2W dosing. Interpatient and intrapatient variability of AUC, respectively, were 31\u201349% and 24% in CSF vs. 59\u2013103% and 80% in plasma. PK variability was not explained by baseline demographics, as sex, age, weight, and CLN2 disease severity score did not appear to impact CSF or plasma PK. No apparent correlation was noted between CSF or plasma PK and incidence of adverse events (pyrexia, hypersensitivity, seizure, and epilepsy) or presence of antidrug antibodies in CSF and serum. There was no relationship between magnitude of CSF exposure and efficacy (change in CLN2 score from baseline), indicating maximum benefit was obtained across the range of exposures with 300\u00a0mg Q2W. Data from this small trial of ultra\u2010rare disease were leveraged to adequately profile cerliponase alfa and support 300\u00a0mg i.c.v. Q2W for CLN2 treatment.<\/jats:p>","DOI":"10.1111\/cts.12925","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T18:46:42Z","timestamp":1605638802000},"page":"635-644","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration"],"prefix":"10.1111","volume":"14","author":[{"given":"Aryun","family":"Kim","sequence":"first","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Grover","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hammon","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"de Hart","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Slasor","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Cherukuri","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitayo","family":"Ajayi","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jacoby","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg\u2013Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Specchio","sequence":"additional","affiliation":[{"name":"Bambino Ges\u00f9 Children\u2019s Hospital IRCCS Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"de Los Reyes","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital and Ohio State University Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[{"name":"NIHR Great Ormond Street Hospital Biomedical Research Centre University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Henshaw","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"e_1_2_10_1_1","first-page":"682","article-title":"CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis)","volume":"13","author":"Kohlsch\u00fctter A.","year":"2016","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.04.008"},{"key":"e_1_2_10_3_1","unstructured":"National Institute of Neurological Disorders and Stroke.NIH Batten Disease Fact Sheet<https:\/\/www.ninds.nih.gov\/Disorders\/Patient\u2010Caregiver\u2010Education\/Fact\u2010Sheets\/Batten\u2010Disease\u2010Fact\u2010Sheet> (2019). Accessed March 11 2020."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2016.10.022"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30368-5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.03.017"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973654"},{"key":"e_1_2_10_8_1","unstructured":"Official Journal of the European Union.European Parliament Council of the European Union. Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001\/20\/EC. L158\u20101\u201076 (2014)."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.05.008"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712649"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.09.003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2014.03.005"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23423"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3570049"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.09.004"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199707000-00001"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-8-7"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/6.4.551"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410040410"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.017"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.01.014"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12925","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:25:04Z","timestamp":1693607104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/cts.12925"],"URL":"https:\/\/doi.org\/10.1111\/cts.12925","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"2020-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}